The Presi, Biologic. & Pharm. of Heska Corp. (NASDAQ: HSKA) is Selling SharesBy Carrie Williams
Following Michael Mcginley’s last HSKA Sell transaction on May 10, 2016, the stock climbed by 22.5%. In addition to Michael Mcginley, one other HSKA executive reported Sell trades in the last month.
Based on Heska Corp.’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $33.43 million and quarterly net profit of $3.35 million. In comparison, last year the company earned revenue of $28.03 million and had a net profit of $1.42 million. The company has a one year high of $63.47 and a one year low of $26.26. HSKA’s market cap is $418.8M and the company has a P/E ratio of 48.74.
The insider sentiment on Heska Corp. has been negative according to 47 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Heska Corp. engages in the research, development, and manufacture of veterinary products. It operates through the two segments: Core Companion Animal Health; and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment supplies blood testing instruments, digital imaging software, heartworm diagnostic tests and preventive products, allergy immunotherapy products, and allergy testing. The Other Vaccines, Pharmaceuticals and Products segment develops and distributes vaccines and pharmaceutical products. The company was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.